Literature DB >> 8587470

Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.

P J Kukkola1, P Savage, Y Sakane, J C Berry, N A Bilci, R D Ghai, A Y Jeng.   

Abstract

The structure-activity relationships of phosphoramidon analogues for inhibition of endothelin-converting enzyme (ECE), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE) were compared. Phosphoramidon inhibited ECE, NEP, and ACE activities with IC50 values of 3.5, 0.034, and 78 microM, respectively. Removal of the rhamnose moiety of phosphoramidon (dipeptide 3) reduced the potency for ECE (IC50 = 70 microM), whereas the potencies for NEP (0.003 microM) and ACE (0.20 microM) were increased. Addition of 2-(2-naphthyl)ethyl to dipeptide 3 improved the potency for ECE (0.55 microM) but weakened the potency for NEP (0.02 microM), and had no significant change for ACE. Interchange between Leu and Trp abolished the inhibitory activities for ECE and NEP, but the compound remained active for ACE. These results suggest that a hydrophobic group in the P1 position of phosphoramidon analogues increases the potency for ECE significantly, whereas compounds containing a free phosphonic acid are optimal for inhibition of NEP and ACE. Furthermore, an aromatic group in the P'2 position is essential for the inhibition of ECE and NEP, but not ACE.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587470

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Crystal structure of Mycobacterium tuberculosis zinc-dependent metalloprotease-1 (Zmp1), a metalloprotease involved in pathogenicity.

Authors:  Davide M Ferraris; Diego Sbardella; Agnese Petrera; Stefano Marini; Beat Amstutz; Massimo Coletta; Peter Sander; Menico Rizzi
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

2.  Opioid receptor function is regulated by post-endocytic peptide processing.

Authors:  Achla Gupta; Ivone Gomes; Jonathan Wardman; Lakshmi A Devi
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

Review 3.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

4.  Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.

Authors:  Edward C Dempsey; Marilee J Wick; Vijaya Karoor; Erica J Barr; Dustin W Tallman; Carol A Wehling; Sandra J Walchak; Sven Laudi; Mysan Le; Masahiko Oka; Susan Majka; Carlyne D Cool; Karen A Fagan; Dwight J Klemm; Louis B Hersh; Norma P Gerard; Craig Gerard; York E Miller
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

5.  Endothelin-converting enzyme 2 differentially regulates opioid receptor activity.

Authors:  A Gupta; W Fujita; I Gomes; E Bobeck; L A Devi
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

6.  Endothelin-converting enzymes degrade intracellular β-amyloid produced within the endosomal/lysosomal pathway and autophagosomes.

Authors:  Javier Pacheco-Quinto; Elizabeth A Eckman
Journal:  J Biol Chem       Date:  2013-01-02       Impact factor: 5.157

7.  [D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.

Authors:  Michael Zimmermann; Carla Sabine Jung; Hartmut Vatter; Andreas Raabe; Volker Seifert
Journal:  Neurosurg Rev       Date:  2002-11-19       Impact factor: 3.042

Review 8.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

9.  Proteolysis controls endogenous substance P levels.

Authors:  Andrew J Mitchell; Anna Mari Lone; Arthur D Tinoco; Alan Saghatelian
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

10.  Endosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteries.

Authors:  A J McNeish; B T Roux; S-B Aylett; A M Van Den Brink; G S Cottrell
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.